Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2021-09-02 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly lists the name of the executive (Adam Steensberg), their position (EVP), the nature of the transaction (Sale of Shares), and the transaction details. This is a classic Director's Dealing notification.
2021-09-02 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). This is a classic 'Director's Dealing' notification, which is specifically categorized under the DIRS code. The document length is short and serves as an official notification of these transactions, which are further detailed in an attached file.
2021-09-02 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a company announcement (No. 54/2021) from Zealand Pharma, dated August 31, 2021, explicitly stating the 'Total number of shares and voting rights in Zealand Pharma at August 31, 2021'. This type of filing, which reports changes in the total number of outstanding shares and voting rights, is a mandatory disclosure often related to capital structure updates or regulatory requirements concerning share ownership thresholds. While it touches upon capital structure, it is a specific, periodic disclosure about the current share count, not a general financing activity (CAP) or a share repurchase (POS). It is a notification of a change in the capital base, which aligns closely with 'Share Issue/Capital Change' (SHA) or, given its nature as a mandatory regulatory update on share count, it could also fall under a general regulatory filing. However, since it directly reports the final count of shares and voting rights following a capital event (warrant exercise mentioned), SHA is the most precise fit among the specific codes, as it relates directly to the capital structure components being reported. Given the context of mandatory disclosure under the Danish Capital Markets Act regarding share capital, SHA is the best fit.
2021-08-31 English
Share Issue/Capital Change 2021
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement (No. 53/2021) from Zealand Pharma detailing an increase in its share capital resulting from the exercise of employee warrants. This action directly involves changes to the company's capital structure and share count. This aligns precisely with the definition of 'Share Issue/Capital Change' (Code: SHA), which covers updates on new share issues or capital structure changes. Although it mentions amendments to the Articles of Association, the core subject is the capital increase itself, not a general governance report (CGR) or a general regulatory filing (RNS). It is not a financing announcement (CAP) as it is an internal employee warrant exercise, not external fundraising.
2021-08-20 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for H1 2021' and contains detailed financial results, business highlights, and operational updates for the first half of the fiscal year. It provides substantive financial data (revenue, operating expenses, cash position) and management analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-12 English
Zealand Pharma A/S – Final Transactions Under Share Repurchase Program
Transaction in Own Shares Classification · 100% confidence The document consists entirely of a tabular log of stock market transactions, including volume, price, venue (XCSE), and timestamps. This is a standard record of share repurchases or transactions in own shares, which is typically disclosed by companies to report buyback activity. Based on the provided categories, this fits the 'Transaction in Own Shares' (POS) classification.
2021-07-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.